CL2014000418A1 - Particula de peptido que comprende un ligando en su superficie externa y uno o dos peptidos anfifilicos, los cuales comprenden un segmento peptidilo hidrofobico y un segmento peptidilo hidrofilico; y su uso para el suministro de un agente activo a una celula. - Google Patents

Particula de peptido que comprende un ligando en su superficie externa y uno o dos peptidos anfifilicos, los cuales comprenden un segmento peptidilo hidrofobico y un segmento peptidilo hidrofilico; y su uso para el suministro de un agente activo a una celula.

Info

Publication number
CL2014000418A1
CL2014000418A1 CL2014000418A CL2014000418A CL2014000418A1 CL 2014000418 A1 CL2014000418 A1 CL 2014000418A1 CL 2014000418 A CL2014000418 A CL 2014000418A CL 2014000418 A CL2014000418 A CL 2014000418A CL 2014000418 A1 CL2014000418 A1 CL 2014000418A1
Authority
CL
Chile
Prior art keywords
peptidyl segment
ligand
cell
supply
active agent
Prior art date
Application number
CL2014000418A
Other languages
English (en)
Inventor
Christian Dittrich
Gaudenz Danuser
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of CL2014000418A1 publication Critical patent/CL2014000418A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/711Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material
    • A61K9/4825Proteins, e.g. gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5169Proteins, e.g. albumin, gelatin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2014000418A 2011-08-23 2014-02-20 Particula de peptido que comprende un ligando en su superficie externa y uno o dos peptidos anfifilicos, los cuales comprenden un segmento peptidilo hidrofobico y un segmento peptidilo hidrofilico; y su uso para el suministro de un agente activo a una celula. CL2014000418A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161526526P 2011-08-23 2011-08-23

Publications (1)

Publication Number Publication Date
CL2014000418A1 true CL2014000418A1 (es) 2014-07-25

Family

ID=46826904

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014000418A CL2014000418A1 (es) 2011-08-23 2014-02-20 Particula de peptido que comprende un ligando en su superficie externa y uno o dos peptidos anfifilicos, los cuales comprenden un segmento peptidilo hidrofobico y un segmento peptidilo hidrofilico; y su uso para el suministro de un agente activo a una celula.

Country Status (19)

Country Link
US (1) US8828928B2 (es)
EP (1) EP2748182B1 (es)
JP (1) JP2014524477A (es)
KR (1) KR20140068087A (es)
CN (1) CN104011065B (es)
AU (1) AU2012298824B2 (es)
BR (1) BR112014004014A2 (es)
CA (1) CA2845886A1 (es)
CL (1) CL2014000418A1 (es)
DK (1) DK2748182T3 (es)
ES (1) ES2610779T3 (es)
HU (1) HUE031511T2 (es)
IL (1) IL231005A0 (es)
MX (1) MX2014002062A (es)
PT (1) PT2748182T (es)
RU (1) RU2014110901A (es)
SG (1) SG11201400073SA (es)
WO (1) WO2013028843A1 (es)
ZA (1) ZA201401210B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8153435B1 (en) 2005-03-30 2012-04-10 Tracer Detection Technology Corp. Methods and articles for identifying objects using encapsulated perfluorocarbon tracers
WO2017139746A1 (en) * 2016-02-11 2017-08-17 Mark Daniels Posh inhibitor complex biomolecules and amphiphile micelles
CA3018561A1 (en) 2016-03-21 2017-09-28 Rhode Island Council On Postsecondary Education Ph-sensitive peptides
CN116908452A (zh) * 2016-12-16 2023-10-20 布里格姆及妇女医院股份有限公司 用于疾病的早期检测的蛋白质冠传感器阵列的系统和方法
CN106832003B (zh) * 2017-02-15 2021-01-05 中国药科大学 一种酸敏性多肽及其应用
KR20200140291A (ko) * 2018-04-06 2020-12-15 애마 세러퓨틱스 인코포레이티드 치료제의 제어된 방출을 위한 조성물
CN114516819B (zh) * 2022-02-25 2024-02-27 顺毅宜昌化工有限公司 一种n,n’-二乙酰基肼的制备方法
WO2023244536A2 (en) * 2022-06-13 2023-12-21 Neubase Therapeutics, Inc. Oligonucleotide analogue formulations
CN116004221B (zh) * 2022-12-15 2023-12-19 湖南卓润生物科技有限公司 环肽的新应用、吖啶标记复合物与制备方法、检测试剂盒

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3270960A (en) 1964-09-11 1966-09-06 Sperry Rand Corp Fluid sensor
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3872925A (en) 1973-04-24 1975-03-25 Gearhart Owen Industries Through-tubing bridge plug
US3842067A (en) 1973-07-27 1974-10-15 American Home Prod Synthesis of(des-asn5)-srif and intermediates
JPS5726506B2 (es) 1974-03-08 1982-06-04
US4105603A (en) 1977-03-28 1978-08-08 The Salk Institute For Biological Studies Peptides which effect release of hormones
US4511390A (en) 1983-06-10 1985-04-16 E. I. Du Pont De Nemours And Company Aralkylcarbamoyl peptide alcohols
US5643873A (en) 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
US5625048A (en) 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
US5654276A (en) 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
FR2736642B1 (fr) 1995-07-10 1997-09-12 Pasteur Institut Immunovecteurs, notamment anticorps et fragments d'anticorps utilisables pour le transport intracellulaire et intranucleaire de principes biologiquement actifs notamment d'haptenes, de proteines et d'acides nucleiques
US6124128A (en) 1996-08-16 2000-09-26 The Regents Of The University Of California Long wavelength engineered fluorescent proteins
CA2377244A1 (en) 1999-08-02 2001-02-08 Synt:Em S.A. Computational design methods for making molecular mimetics
WO2002068605A2 (en) 2001-02-26 2002-09-06 The Regents Of The University Of California Non-oligomerizing tandem fluorescent proteins
EP4023240A1 (en) 2004-07-06 2022-07-06 3D Matrix, Inc. Purified amphiphilic peptide compositions and uses thereof
AU2009221419B2 (en) * 2008-02-01 2013-09-26 Alpha-O Peptides Ag Self-assembling peptide nanoparticles useful as vaccines
AU2009243187C1 (en) * 2008-04-28 2015-12-24 President And Fellows Of Harvard College Supercharged proteins for cell penetration

Also Published As

Publication number Publication date
CA2845886A1 (en) 2013-02-28
PT2748182T (pt) 2017-01-20
HUE031511T2 (en) 2017-07-28
ES2610779T3 (es) 2017-05-03
CN104011065B (zh) 2017-06-30
CN104011065A (zh) 2014-08-27
SG11201400073SA (en) 2014-03-28
AU2012298824B2 (en) 2017-06-01
US8828928B2 (en) 2014-09-09
NZ622045A (en) 2016-02-26
ZA201401210B (en) 2015-12-23
JP2014524477A (ja) 2014-09-22
US20130064895A1 (en) 2013-03-14
IL231005A0 (en) 2014-03-31
RU2014110901A (ru) 2015-09-27
AU2012298824A1 (en) 2014-03-20
MX2014002062A (es) 2014-05-28
KR20140068087A (ko) 2014-06-05
WO2013028843A1 (en) 2013-02-28
BR112014004014A2 (pt) 2020-10-27
DK2748182T3 (en) 2017-02-06
EP2748182A1 (en) 2014-07-02
EP2748182B1 (en) 2016-10-19

Similar Documents

Publication Publication Date Title
CL2014000418A1 (es) Particula de peptido que comprende un ligando en su superficie externa y uno o dos peptidos anfifilicos, los cuales comprenden un segmento peptidilo hidrofobico y un segmento peptidilo hidrofilico; y su uso para el suministro de un agente activo a una celula.
CL2015000345A1 (es) Uso de una combinación para el melanoma que comprende la administración de cobimetinib y vemurafenib.
ZA201506916B (en) Microstructure array for delivery of active agents
SMT201600398B (it) Inibitori di proteina chinasi (varianti), uso di questi nel trattamento di malattie oncologiche e composizione farmaceutica basata su questi
BR112015022625A2 (pt) micromatrizes para entrega de agente terapêutico e métodos de uso
EP3000144A4 (en) Surface treated silicon containing active materials for electrochemical cells
CL2012003281A1 (es) Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica.
CO6910187A2 (es) Composiciones parasiticidas que comprenden un agente activo isoxazolina, sus métodos y usos
CL2014002093A1 (es) Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
UY35847A (es) Un método para controlar la roya
CO6801774A2 (es) Compuestos de benzotiazol y su uso farmacéutico
EP2984642A4 (en) MAPPING OF ACTIVE AND INACTIVE BUILDING ZONES FOR AUTONOMOUS PILOTAGE
CR20140487A (es) Peliculas de capas multiples capaces de liberar ingredientes activos por un periodo limitado de tiempo
CL2014001172A1 (es) Un portador para la liberacion controlada de agentes activos que comprende un nucleo de cabonato de calcio y un agente activo, y un recubrimiento que encapsula al nucleo; metodo para preparar el portador, y su uso en controlar la liberacion de un agente activo
CL2013000718A1 (es) Un complejo de inclusion que comprende a) una ciclodextrina, b) fulvestrant y c) un portador; su metodo de preparacion; formulacion y forma de dosificacion que comprende al complejo; preparacion que comprende al complejo o a la formulación; y su uso en el tratamiento del cancer y lupus eritematoso sistemico, entre otras enfermedades.
BR112013020368A2 (pt) peptídeos modificados hidrofóbicos e uso dos mesmos para alvo específico no fígado
BR112013014203A2 (pt) peptídeo anfifílico bicéfalo, hidrogel e método para liberação de um agente bioativo
ECSP17044282A (es) Formulación de relación fija de insulina glargina/lixisenatida
BR112015002706A2 (pt) niclosamida e seus derivados para uso no tratamento de tumores sólidos
CL2014001861A1 (es) Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia.
CL2013000735A1 (es) Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para el tratamiento de enfermedades y condiciones de la piel, tales como rosacea, daño solar cronico, psoriasis, entre otras; kit farmaceutico.
FR3003396B1 (fr) Structures semi-conductrices dotees de regions actives comprenant de l'ingan
CL2014000267A1 (es) Formulacion farmaceutica liquida que comprende ketoprofeno, amitriptilina y oximetazolina; kit farmaceutico; metodo para prevenir o tratar la inflamacion.
CL2014003525A1 (es) Composicion farmaceutica que comprende fimasartan, hidroclorotiazida y un aglutinante; procedimiento de preparacion; su uso en el tratamiento de hipertension.
CR20130689A (es) Cepa ts-15 de paenibacillus alvei y su uso en el control de organismos patógenos